Category: Baxter InternationalSyndicate content

Baxter reports Q2 sales jump, narrows earnings guidance

July 17, 2014 by Brad Perriello

Baxter reports 2nd-quarter sales growth of more than 16% and beats earnings expectations, but narrows its full-year earnings guidance.

Baxter reports Q2 sales jump, narrows earnings guidance

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Conor MedSystems can't slip $100 million breach of contract lawsuit | Medtech legal news for the week of May 26, 2014

May 26, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: J&J's Conor MedSystems can't slip $100M Biotronik lawsuit; Supreme Court declines review of Baxter/Fresenius patent row; Medtronic, Edwards ink $750M heart valve settlement; Pa. Supreme Court to review $28M Zimmer verdict; Laid off Italian workers sue Haemonetics.

J&J's Conor MedSystems can't slip $100M Biotronik lawsuit

May 20, 2014 by Brad Perriello

J&J's Conor Medsystems can't slip $100M Biotronik lawsuit

Supreme Court declines review of Baxter/Fresenius patent row

May 19, 2014 by Brad Perriello

Fresenius escapes for good a $24 million patent infringement loss to dialysis rival Baxter International after the U.S. Supreme court declines to review the case.

Supreme Court declines review of Baxter/Fresenius patent row

Baxter lands FDA nod for next-gen Sigma Spectrum infusion pump

May 13, 2014 by Arezu Sarvestani

Illinois-based Baxter lands FDA clearance for its next-generation Sigma Spectrum infusion pump, which includes a "Master Drug Library" of facility-specific drugs and dosing parameters.

Baxter lands FDA nod for library-enabled SIGMA Spectrum infusion pump

Baxter (NYSE:BAX) this week touted FDA clearance for its next-generation Sigma Spectrum infusion pump with safety software that allows hospitals to set drug delivery parameters to minimize dosing errors.

Baxter pump recall gets FDA's highest-risk label following 9 severe injuries

May 5, 2014 by Arezu Sarvestani

Baxter's infusion pump recall is associated with 9 severe adverse events and more than 3,500 complaints, getting the FDA's attention and highest-risk warning label.

Baxter pump recall gets FDA's highest-risk label following 9 severe injuries

Medtech maker Baxter (NYSE:BAX) got the FDA's highest-risk warning after recalling a series of infusion pumps due to a software issue that could lead the devices to malfunction.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp